Mechanisms underlying purinergic P2X7 receptor antagonism in maintaining urothelial barrier function against acrolein-induced damage and cytotoxicity

Taidi Z1, Liang C1, Mansfield K2, Moore K3, Liu L1

Research Type

Basic Science / Translational

Abstract Category

Pharmacology

PRIZE AWARD: Best in Category Prize - Pharmacology
Abstract 227
Autonomic Pharmacology
Scientific Podium Short Oral Session 12
Wednesday 4th September 2019
16:30 - 16:37
Hall H2
Basic Science Painful Bladder Syndrome/Interstitial Cystitis (IC) Pharmacology Cell Culture
1.University of New South Wales, 2.University of Wollongong, 3.St.George hospital, University of New South Wales
Presenter
Z

Zhinoos Taidi

Links

Abstract

Hypothesis / aims of study
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a urinary bladder disorder with an unknown etiology. It is known that cyclophosphamide can cause cystitis and bladder pain in patients who undergo chemotherapy, a condition induced by acrolein, the highly toxic metabolite of cyclophosphamide. The mechanism by which acrolein causes cystitis is likely due to its direct damage to the urothelium, leading to subsequent inflammatory responses (1). The role of purinergic P2X7 receptor (P2X7R) in mediating bladder inflammation has recently come into attention. Previous studies have shown that P2X7R antagonists inhibited acrolein-induced inflammatory changes in the bladder such as oedema, haemorrhage, loss of urothelium and apoptosis (2, 3) and restored bladder function (3).

This study aimed to determine whether high concentrations of extracellular ATP can induce P2X7R-dependent large pore formation on urothelial cell membranes of the porcine bladder. The study also sought to explore the effect of acrolein on the integrity of urothelial cells and whether inhibition of P2X7R activities can protect against acrolein-induced damage and maintain urothelial barrier function.
Study design, materials and methods
The property of P2X7R-dependent large pore formation was investigated by measuring high concentrations of ATP- and Bz-ATP-evoked YO-PRO-1 uptake into cultured porcine urothelial cells. YO-PRO-1 is a fluorescent dye with a molecular weight of 630 Daltons that can only enter cells via abnormal large pores on the membrane, followed by binding to the nucleic acid of the cells and generating a fluorescence signal. Urothelial cells (50000 cells/well) isolated from freshly dissected female porcine bladder were plated in 96-well plates and incubated at 37 ºC, 5% CO2 for 72 h. Prior to performing the assay, urothelial cells were pre-incubated with ATP (300 µM) or Bz-ATP (300 μM) for 30 min, and then the culture media was gently replaced with 180 μl of the HEPES buffer. ATP or Bz-ATP (both at 300 μM) was added into the wells and the plate was immediately read with the FLUOstar OPTIMA Plate Reader at 30 s intervals for 15 readings (485 nm excitation and 520 nm emission). 20 μl of YO-PRO-1 iodide (491/509) (2 μM) was added between the 3rd and 4th reading. P2X7R antagonists, AZ11645373 (100 μM) or A804598 (1 μM) were added 30 min before the addition of agonists.  

The effect of acrolein on the integrity of urothelial cells was studied by measuring the trans-epithelial electrical resistance (TEER), a well-known indicator of cell monolayer integrity. Urothelial cells (100000 cells/well) were plated in permeable transwell inserts and cultured in DMEM media. TEER values were measured using an EVOM epithelial volt/ohm meter. When a stable TEER reading was achieved, the cells were treated with acrolein (50 µM) and TEER values were measured at the time of treatment (taken as the baseline) and then in 2, 4, 24 and 48 h after the treatment. To check the involvement of P2X7R, cells were incubated with A804598 (10 μM), 30 min before and together with acrolein. Furthermore, immunocytochemistry of ZO-1 tight junction protein was performed on urothelial cells treated similarly as the TEER experiment.
Results
P2X7R-dependent YO-PRO-1 dye uptake: High concentrations of ATP (300 μM) and the selective P2XR7 agonist Bz‐ATP (300 μM) induced a long‐lasting increase of YO‐PRO‐1 fluorescence intensity in urothelial cells, indicating the formation of large pores on cell membranes. The P2X7R antagonist A804598 (1 μM) alone showed no difference compared to control, however it completely abolished ATP and Bz-ATP induced dye uptake (Figure 1). The similar results were obtained when another P2X7R antagonist AZ11645373 (100 μM) was used (data not shown).
Effects of P2X7R antagonist A804598 on acrolein induced urothelial cell damage: Exposure of urothelial cells to acrolein (50 µM) caused a persistent damage to urothelial barrier function as indicated by the prolonged and substantial reduction of TEER values (Figure 2A) as well as the loss of tight junction protein ZO-1 immunoreactivity (Figure 2C) compared to control (Figure 2B). Pre‐treating urothelial cells with A804598 (10 µM) reversed acrolein‐induced TEER reduction to the level equivalent to the control (Figure 2A). Acrolein‐induced damage to ZO‐1 tight junction was attenuated by the blockade of P2X7R (Figure 2D).
Interpretation of results
In this study, we have demonstrated that the activation of P2X7R with high concentrations of agonists can open large pore on urothelial cells, a property that can lead to the release of inflammatory cytokines and apoptotic cell death. Inhibition of P2X7R activity by its antagonists can significantly protect the cells from pore formation. The study has also shown the damaging effect of acrolein on the barrier function of porcine primary urothelial cells, and the protective effect of P2X7R blockade against the damage. This result points out the important role of P2X7R in urinary bladder cystitis which is a major side effect of the chemotherapy agent cyclophosphamide and indicates the possible therapeutic role for P2X7R antagonists in this type of bladder cystitis.
Concluding message
This is the first report showing that acrolein can disrupt cell integrity and increase permeability in cultured urothelial cells, and the disruptive effect of acrolein was greatly attenuated by P2X7R antagonism. Taken together, these findings may underline the role of P2X7R in bladder inflammation and could contribute to the understanding of other forms of painful bladder syndrome
Figure 1 Figure 1. YO‐PRO‐1 uptake in porcine bladder urothelial cells.
Figure 2 Figure 2. Acrolein induced urothelial cell damage.
References
  1. Wang CC, Weng TI, Wu ET, Wu MH, Yang RS, Liu SH (2013). Involvement of interleukin-6-regulated nitric oxide synthase in hemorrhagic cystitis and impaired bladder contractions in young rats induced by acrolein, a urinary metabolite of cyclophosphamide. Toxicological sciences: an official journal of the Society of Toxicology.;131(1):302-10.
  2. Martins JP, Silva RB, Coutinho-Silva R, Takiya CM, Battastini AM, Morrone FB (2012). The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice. British journal of pharmacology.165 (1), 183-96.
  3. Taidi Z, Mansfield K J, Moore K H, Liu L (2018). Blockage of purinergic P2X7 receptor reduces mucosa damage and restores diminished contractility in an ex-vivo inflammation model of porcine bladder. Neurourology and Urodynamics 37: S104-S106.
Disclosures
<span class="text-strong">Funding</span> None <span class="text-strong">Clinical Trial</span> No <span class="text-strong">Subjects</span> None